Explore

Trendline Trendline
CicadaBio Presents New Data on CC-18 for Muscle-Preservation Weight Loss at ADA 2026

CicadaBio Presents New Data on CC-18 for Muscle-Preservation Weight Loss at ADA 2026

CicadaBio Presents New Data on CC-18 for Muscle-Preservation Weight Loss at ADA 2026
Trendline Trendline
CicadaBio Presents Promising Preclinical Data on Obesity Treatment at ADA 2026

CicadaBio Presents Promising Preclinical Data on Obesity Treatment at ADA 2026

CicadaBio Presents Promising Preclinical Data on Obesity Treatment at ADA 2026
Trendline Trendline
OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026, Highlighting Potential Benefits for Obesity Treatment

OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026, Highlighting Potential Benefits for Obesity Treatment

OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026, Highlighting Potential Benefits for Obesity Treatment
Trendline Trendline
OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026

OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026

OrsoBio to Present New Data on Mitochondrial Protonophore at ADA 2026
Trendline Trendline
Boehringer Ingelheim's Survodutide Shows Targeted Fat Reduction Despite Less Competitive Weight Loss

Boehringer Ingelheim's Survodutide Shows Targeted Fat Reduction Despite Less Competitive Weight Loss

Boehringer Ingelheim's Survodutide Shows Targeted Fat Reduction Despite Less Competitive Weight Loss
Trendline Trendline
Eli Lilly's Weight Loss Drug Shows Promising Results for Menopausal Women

Eli Lilly's Weight Loss Drug Shows Promising Results for Menopausal Women

Eli Lilly's Weight Loss Drug Shows Promising Results for Menopausal Women
Trendline Trendline
Ambrosia Biosciences Reveals Promising Preclinical Data for Obesity Drug Candidate AMB-702

Ambrosia Biosciences Reveals Promising Preclinical Data for Obesity Drug Candidate AMB-702

Ambrosia Biosciences Reveals Promising Preclinical Data for Obesity Drug Candidate AMB-702
Trendline Trendline
Ascletis Pharma Showcases Promising Obesity Treatments at ADA 2026

Ascletis Pharma Showcases Promising Obesity Treatments at ADA 2026

Ascletis Pharma Showcases Promising Obesity Treatments at ADA 2026
Trendline Trendline
Ascletis Pharma Showcases Obesity Treatment Innovations at ADA 2026

Ascletis Pharma Showcases Obesity Treatment Innovations at ADA 2026

Ascletis Pharma Showcases Obesity Treatment Innovations at ADA 2026
Trendline Trendline
Boehringer Ingelheim's Survodutide Shows Efficacy in Obesity Trials but Faces Safety Concerns

Boehringer Ingelheim's Survodutide Shows Efficacy in Obesity Trials but Faces Safety Concerns

Boehringer Ingelheim's Survodutide Shows Efficacy in Obesity Trials but Faces Safety Concerns
Trendline Trendline
Structure Therapeutics Reports Positive Phase 2b Results for Obesity Drug Aleniglipron

Structure Therapeutics Reports Positive Phase 2b Results for Obesity Drug Aleniglipron

Structure Therapeutics Reports Positive Phase 2b Results for Obesity Drug Aleniglipron
Trendline Trendline
Structure Therapeutics Publishes Phase 2b Trial Results of Aleniglipron for Obesity in Nature Medicine

Structure Therapeutics Publishes Phase 2b Trial Results of Aleniglipron for Obesity in Nature Medicine

Structure Therapeutics Publishes Phase 2b Trial Results of Aleniglipron for Obesity in Nature Medicine